Abstract
Juvenile Idiopathic Arthritis (JIA) is an “umbrella” term which is used to cover Juvenile Rheumatoid Arthritis (JRA) and Juvenile Chronic Arthritis (JCA). Biologic agents are needed when others like NSAIDs (Non-steroidal antiinflammatory agents), DMARDs (Disease modifying antirheumatic drugs) cannot provide or maintain clinical remission, and patients are mainly bound on steroids, which are potential anti-inflammatory drugs with serious well-known side effects to the growing child. TNF-α antagonists are the first anti-cytokine agents introduced in the last decade. However, there are important subtypes, such as systemic JIA which are resistant to these drugs, because IL-1 β (Interleukin 1 β) activation is shown to be the main pathway. One of the most frequently asked questions about biologics, particularly ETN (Etanercept), is the duration of the treatment, regarding both the safety and efficacy. Regarding the current literature, ETN seems to be effective and safe in treating the children with JIA. The high dose regimen (6 mg/kg) of infliximab, a TNF monoclonal antibody, has achieved better results on JIA and is now used in pediatric rheumatology practice. Adalimumab, another TNF inhibitor and abatacept (CTLA-4) were also shown to be effective and safe in JIA. Anakinra, canakinumab, and tocilizumab are the ones recently studied, and they are shown to be effective particularly for systemic arthritis.
Keywords: Juvenile idiopathic arthritis, treatment, biologic agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Using Biologic Agents in Pediatric Rheumatologic Diseases
Volume: 9 Issue: 1
Author(s): Erbil Unsal
Affiliation:
Keywords: Juvenile idiopathic arthritis, treatment, biologic agents
Abstract: Juvenile Idiopathic Arthritis (JIA) is an “umbrella” term which is used to cover Juvenile Rheumatoid Arthritis (JRA) and Juvenile Chronic Arthritis (JCA). Biologic agents are needed when others like NSAIDs (Non-steroidal antiinflammatory agents), DMARDs (Disease modifying antirheumatic drugs) cannot provide or maintain clinical remission, and patients are mainly bound on steroids, which are potential anti-inflammatory drugs with serious well-known side effects to the growing child. TNF-α antagonists are the first anti-cytokine agents introduced in the last decade. However, there are important subtypes, such as systemic JIA which are resistant to these drugs, because IL-1 β (Interleukin 1 β) activation is shown to be the main pathway. One of the most frequently asked questions about biologics, particularly ETN (Etanercept), is the duration of the treatment, regarding both the safety and efficacy. Regarding the current literature, ETN seems to be effective and safe in treating the children with JIA. The high dose regimen (6 mg/kg) of infliximab, a TNF monoclonal antibody, has achieved better results on JIA and is now used in pediatric rheumatology practice. Adalimumab, another TNF inhibitor and abatacept (CTLA-4) were also shown to be effective and safe in JIA. Anakinra, canakinumab, and tocilizumab are the ones recently studied, and they are shown to be effective particularly for systemic arthritis.
Export Options
About this article
Cite this article as:
Unsal Erbil, Using Biologic Agents in Pediatric Rheumatologic Diseases, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (1) . https://dx.doi.org/10.2174/187152310790711629
DOI https://dx.doi.org/10.2174/187152310790711629 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Angiogenesis and Angiogenesis Inhibitors: a New Potential Anticancer Therapeutic Strategy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders An Update on the Emerging Role of Wnt/β-catenin, SYK, PI3K/AKT, and GM-CSF Signaling Pathways in Rheumatoid Arthritis
Current Drug Targets Clinical Pharmacokinetics of Ibuprofen Arginine
Current Clinical Pharmacology Modulation of Inducible Nitric Oxide Synthase Activation by Immuno-suppressive Drugs
Current Drug Metabolism Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery Preface
Current Drug Therapy Life or Death? A Physiogenomic Approach to Understand Individual Variation in Responses to Hemorrhagic Shock
Current Genomics Identifying the Hub Genes and Immune Cell Infiltration in Synovial Tissue between Osteoarthritic and Rheumatoid Arthritic Patients by Bioinformatic Approach
Current Pharmaceutical Design Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus
Current Pharmaceutical Design New Look at Therapeutic Strategies for Blocking Costimulatory Signal in Experimental and Pre-Clinical Transplantation
Current Drug Safety Pathophysiology of Thrombosis and Potential Targeted Therapies in Antiphospholipid Syndrome
Current Vascular Pharmacology Computational Analysis of the Interaction between Ligand-Receptor Pairs
Current Pharmaceutical Design Enhanced Generation of Leukotriene B4 From Calcium Ionophore- Stimulated Rat Peritoneal Inflammatory Cells: A Possible Clinical Relevance
Current Drug Targets - Inflammation & Allergy Editorial [Hot Topic: New Opportunities in Treatment of Arthritis (Guest Editor: Uday Saxena)]
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Marine n-3 Fatty Acids for Cardiovascular Risk Reduction and Disease Control in Rheumatoid Arthritis: “Kill Two Birds with One Stone”?
Current Pharmaceutical Design Recent Advances in PDE4 Inhibitors as Immunoregulators and Anti- Inflammatory Drugs
Current Pharmaceutical Design Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond
Current Medicinal Chemistry Lipoprotein Like Nanoparticles Used in Drug and Gene Delivery
Current Pharmaceutical Design Inhibitory Effect of Selective Cyclooxygenase-2 Inhibitor Etoricoxib on Human Organic Anion Transporter 3 (hOAT3)
Drug Metabolism Letters Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design